The growing global prevalence of type 1 and 2 diabetes, driven by obesity and other forces, is creating strong clinical demand for a diverse set of diagnosis, monitoring and treatment products that are steadily evolving to better manage the disease.
PRLog (Press Release) – Jul 20, 2010 – The diabetes market, which includes both pharmaceuticals and medical devices, is large, and is growing steadily for four main reasons. First, the prevalence of diabetes is increasing, particularly that of type 2 in developed countries and those with increasing prosperity. Type 1 diabetes is also increasing, though less dramatically. Second, type 2 diabetes is responsive to drug therapy, and there is a continuing search for newer, better pharmacological agents. Third, insulin, required for all cases of type 1 and some of type 2 diabetes, poses administration problems, offering opportunities for new delivery systems. Fourth, patients with diabetes must monitor their condition by frequently checking the level of glucose in their blood, and there are ongoing attempts to make this process easier and more user-friendly by developing more advanced (and expensive) devices. A fifth driving factor in the diabetes marketplace is the search for a fundamentally better way to manage the disease. Some options are mainly surgical—transplants of pancreatic cells, for example. Another focus for research is to combine glucose monitoring with insulin administration in a self-controlled wearable device. And further in the future are prospects for using stem cells to grow new beta cells, and for using genetic knockout techniques to block the metabolic processes that cause diabetes. The result is a $36 billion global market that is on pace to cross $100 billion annually within a few years, according to a new report, "Products, Technologies, Markets and Opportunities in Diabetes Management Worldwide, 2009-2018", from leading medtech industry research firm MedMarket Diligence, LLC.
"We are seeing a real and measureable expansion in the diabetes patient population as a result of growth in obesity and demographics that is simply adding tremendous clinical demand for effective products," says Patrick Driscoll, president of MedMarket Diligence. According to Driscoll, clinical research has repeatedly demonstrated the value of diabetes management products in reducing the risk of life-threatening complications, both for type 1 and type 2 diabetes. The market for diabetes management products is also evolving as manufacturers continue to develop new diagnosis, monitoring and treatment products.
This MedMarket Diligence Report #D510, "Diabetes Management Worldwide", details the worldwide incidence and prevalence by country/region of type 1 and type 2 diabetes and details the current and projected market for diagnostic and therapeutic products in the management of diabetes, including anti-diabetic drugs, alternative insulin types, blood glucose monitoring (including continuous monitoring devices), insulin pumps, and other established and emerging products in diabetes management. The report provides an emphasis of detail on the status of development of novel products including noninvasive monitoring, oral/inhaled/other insulin delivery. The report details the clinical and technology developments underlying this huge and evolving worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity. Separate size, growth and competitor share data are presented for the U.S., European, Asia/Pacific and Rest of World. The report profiles active companies including detailed profile information on major competitors, brief profiles of companies with less sizeable current or potential positions in the market, plus additional profiles of companies with novel or advanced research activities in the market.
The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.
The report is described in detail at http://mediligence.com/rpt/rpt-d510.htm.
The report may be purchased for download from http://mediligence.com/store/page34.html.
More from advanced medtech blog...